Press Releases

60% relapse free survival at 1 year post-transplant 79% overall survival at 1 year post-transplant Median overall survival of 20.6 months BOSTON , Dec. 13, 2021 (GLOBE NEWSWIRE) --   Aprea Therapeutics, Inc. (Nasdaq: APRE ), a biopharmaceutical company focused on developing and commercializing